A post-marketing safety study of ramucirumab with FOLFIRI in patients with metastatic colorectal cancer

BACKGROUND: Ramucirumab [human vascular endothelial growth factor (VEGF) receptor-2 monoclonal antibody] + levofolinate, fluorouracil, and irinotecan (FOLFIRI) was approved for the treatment of metastatic colorectal cancer (CRC) in Japan based on the results from the phase 3 RAISE trial (NCT01183780...

Descripción completa

Detalles Bibliográficos
Autores principales: Masuishi, Toshiki, Nagaoka, Soshi, Jin, Long, Yoshizawa, Kenichi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AME Publishing Company 2022
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9459187/
https://www.ncbi.nlm.nih.gov/pubmed/36092332
http://dx.doi.org/10.21037/jgo-21-863

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9459187/
https://www.ncbi.nlm.nih.gov/pubmed/36092332
http://dx.doi.org/10.21037/jgo-21-863

Ejemplares similares